Pao, William

Publications

Sort by

Co-Author Network

selected publications

Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. 2025 GET IT
Elucidating the Cell Surfaceome to Accelerate Cancer Drug Development. Cancer discovery. 2024 Academic Article GET IT
Times cited: 9
The NIH-led research response to COVID-19. Science (New York, N.Y.). 2023 Academic Article GET IT
Times cited: 37
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Journal of medicinal chemistry. 2022 Academic Article GET IT
Times cited: 24
Paradigms for the development of transformative medicines-lessons from the EGFR story. Annals of oncology : official journal of the European Society for Medical Oncology. 2022 Editorial Article GET IT
Times cited: 3
Catalyzing the field of precision oncology, one basket at a time. Nature medicine. 2018 Academic Article GET IT
Times cited: 3
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. Cancer discovery. 2018 Review GET IT
Times cited: 71
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2017 Academic Article GET IT
Times cited: 29
From academia to industry: a road more travelled. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 4
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 11
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer research. 2017 Academic Article GET IT
Times cited: 118
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Molecular oncology. 2017 Academic Article GET IT
Times cited: 29
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome medicine. 2017 Academic Article GET IT
Times cited: 52
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 41
AACR Cancer Progress Report 2016. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 36

more ...

less ...

Background

education and training

M.D., Yale University School of Medicine 1998
Ph.D., Yale University 1997
A.B., Harvard University 1990

Contact

full name

William Pao

primary email

wip9001@med.cornell.edu

VIVO Weill Cornell Medical College

William Pao Adjunct Professor of Pharmacology (Courtesy) WCM Affiliate

Publications

selected publications

Background

education and training

Contact

full name

primary email